Overview

Sweden is a prominent player for Pharmaceuticals market. With increasing healthcare expenditures, the market projections are lucrative. The country’s regulations mandate that a medicinal product must be approved by the Medicinal Products Agency of Sweden before marketing for human consumption. As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Article 8(3) for New Chemical Entity (NCE) 
  • Article 10 for generic, hybrid and similar biological medicinal products  

Further, the Market Authorization Holder (MAH) has to meet all the requirements listed out by the European Union (EU) and European Economic Area (EEA) considering the UK as a 3rd country post March 30, 2019.

With many global players, the Sweden pharmaceutical market considered as excessively competitive landscape for new-entrants. UK’s move to opt out of EU (Brexit) may also affect any product which share license with UK as Reference Member State (RMS). Enroute, any erroneous submission in may result in huge financial and timeline setbacks affecting product’s market entry. With a clear-cut analysis on market and Regulatory trends, Freyr provides Regulatory strategy to make error-free submissions in line with current EU and Sweden regulations. 

Freyr Expertise 

  • Initial submissions (MAAs) via various procedures- National, Mutual Recognition Procedure (MRP), Decentralized Procedure (DCP) and Centralized Procedure (CP) for innovator, hybrid and generic products 
  • Regulatory consultation and strategic support on submission roadmaps, and procedures 
  • Pre-submission administrative activities such as interaction with Health Authorities (HAs), slot booking for submissions, selection of the RMS and CMS, request to HA to work as RMS 
  • Evaluation of the product and source data from R&D and manufacturing site (executed data) for the EU-specific Regulatory and submission requirements 
  • Compilation and submission of the dossiers to HAs in eCTD format in line with Medical Products Agency of Sweden requirements 
  • Consultation during developments and manufacturing of the medicinal products 
  • Initial submissions for APIs - ASMF/ CEP submissions  
  • Qualified Person (QP), Qualified Person for Pharmacovigilance (QPPV) in EU 
  • Post-approval changes submissions with strategies and compilation/ submission for:   
    • Marketing authorization holder (MAH) transfers 
    • Post-approval quality change like-  
      • Change in manufacturing site, addition/deletion of the site, Batch size change, changes in manufacturing changes, administrative and labeling changes 
    • Monograph updates i.e. compliance to European pharmacopoeia 
    • Changes in container closure system 
    • Change in primary packaging material supplier 
    • Shelf life extension/reduction 
    • Addition of new supplier for active substance 
    • Inclusion of additional source for starting material for drug substance 
  • Impact analysis of Brexit and submission of the relevant changes to HA(s) like- change in Reference Member State (RMS), changes to MAH, addition/ replacement of the batch release and testing sites, changes to the QP, QPPV and Pharmacovigilance system master file (PSMF) (Article 57 notification) 
  • Life cycle maintenance by submission of renewal applications 
  • Support in handling Medical Products Agency of Sweden’s deficiencies with Regulatory strategy and preparation and submission of the response